Pave Salary Data Access Raises Concerns Over Collusion Risk

Pave: Compensation Benchmarking Service Provides Customers Access to Sensitive Non-Public Salary Data, Raising Questions About Potential Collusive Effect

Pave, a compensation benchmarking service, gives over 9,000 companies access to sensitive non- public salary and bonus data, a Capitol Forum investigation found. The platform’s features, including monthly data refreshes and the ability to benchmark against custom peer groups, could facilitate coordination among competing employers, according to a former Pave employee

FDA’s Forthcoming Proposal Could Make Direct-to-Consumer Pharma Ads Prohibitively Long and Expensive to Run; Some Scenarios Could Make Some Current Ads Over Ten Minutes Long

An anticipated proposal from the Food and Drug Administration (FDA) could make direct-to- consumer (DTC) pharmaceutical ads so lengthy as to be cost-prohibitive, according to The Capitol Forum’s...

Jul 30, 2026 Read Now >

Hims & Hers Health: FTC, Utah, and California Sue Hims & Hers Over Deceptive Billing and Privacy Practices

Today, the FTC, as well as regulators in California and Utah, filed a lawsuit against the telehealth provider Hims & Hers Health (HIMS), alleging that the company enrolled consumers in...

Jul 29, 2026 Read Now >

Health Care Weekly: FDA Compounding Advisory Committee Votes Favorably on Six Peptides; Updates on CMS’ Implementation of SDP, Provider Tax Law; Judge Dismisses NSA Case Against HaloMD in GA; CVS Accused of 340B Spread Pricing; OpenAI Faces Unlicensed Practice of Medicine Suit; FDA 483s

The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re following this week...

Jul 29, 2026 Read Now >

Pave: Compensation Benchmarking Service Provides Customers Access to Sensitive Non-Public Salary Data, Raising Questions About Potential Collusive Effect

RELATED ARTICLES | Antitrust Policy

FDA’s Forthcoming Proposal Could Make Direct-to-Consumer Pharma Ads Prohibitively Long and Expensive to Run; Some Scenarios Could Make Some Current Ads Over Ten Minutes Long

Hims & Hers Health: FTC, Utah, and California Sue Hims & Hers Over Deceptive Billing and Privacy Practices

Health Care Weekly: FDA Compounding Advisory Committee Votes Favorably on Six Peptides; Updates on CMS’ Implementation of SDP, Provider Tax Law; Judge Dismisses NSA Case Against HaloMD in GA; CVS Accused of 340B Spread Pricing; OpenAI Faces Unlicensed Practice of Medicine Suit; FDA 483s

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.